Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 1/2012

01.01.2012 | Original Article

A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen)

verfasst von: Michele Reni, Stefano Cereda, Alessia Rognone, Carmen Belli, Michele Ghidini, Simonetta Longoni, Clara Fugazza, Sara Rezzonico, Paolo Passoni, Najla Slim, Giampaolo Balzano, Roberto Nicoletti, Stefano Cappio, Claudio Doglioni, Eugenio Villa

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

PEFG regimen (P:cisplatin, E:epirubicin, F:5-fluorouracil, G:gemcitabine) significantly prolonged progression-free (PFS) and overall survival (OS) of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine. The current trial was aimed at assessing whether the replacement of E with docetaxel (D) may improve 6 months PFS (PFS6).

Methods

Chemo-naive patients with stage III or metastatic PA received P (30 mg/m2 day 1 and 15), G (800 mg/m2 day 1 and 15), and capecitabine (1,250 mg/m2/day days 1–28, without a break) and were randomized to receive either D at 25–30 mg/m2 day 1 and 15 (arm A: PDXG regimen) or E at 30 mg/m2 day 1 and 15 (arm B: PEXG regimen). Cycles were repeated every 28 days for a maximum of 6 months. The Fleming design was used to calculate the sample size on the probability of being PFS6. Assuming P0 = 40% and P1 = 60%, α = 0.05 and β = 0.10; the study was to enroll 52 patients per arm.

Results

Between July 2005 and September 2008, 105 patients were enrolled, stratified by stage and randomized. Patients’ characteristics were (A/B) the following: median age 61/59, PS >70 92/88%, metastatic disease 66/65%. PFS6 was 58%, and median OS was 11 months in both arms. A partial response was observed in 60/37% of patients. Main per cycle G3-4 toxicity was the following: neutropenia 4/13%, thrombocytopenia 2/4%, anemia 4/4%, and fatigue 6/3%.

Conclusions

The inclusion of D instead of E yielded more objective response and less G3-4 neutropenia but did not improve PFS and OS. The present trial confirms the relevant impact on outcome of advanced PA of 4-drug regimens.
Literatur
1.
Zurück zum Zitat Cascinu S, Falconi M, Valentini V et al (2010) Pancreatic cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:55–58CrossRef Cascinu S, Falconi M, Valentini V et al (2010) Pancreatic cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:55–58CrossRef
2.
Zurück zum Zitat Reni M, Sartori N, Mambrini A et al (2010) An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change? Anticancer Drug 21:459–464CrossRef Reni M, Sartori N, Mambrini A et al (2010) An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change? Anticancer Drug 21:459–464CrossRef
3.
Zurück zum Zitat Reni M, Pasetto LM, Passardi A et al (2011) Treatment trends in metastatic pancreatic cancer patients: is it time to change? Dig Liv Dis 43:225–230CrossRef Reni M, Pasetto LM, Passardi A et al (2011) Treatment trends in metastatic pancreatic cancer patients: is it time to change? Dig Liv Dis 43:225–230CrossRef
4.
Zurück zum Zitat Berlin JD, Catalano P, Thomas JP et al (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: eastern cooperative oncology group trial E2297. J Clin Oncol 20:3270–3275PubMedCrossRef Berlin JD, Catalano P, Thomas JP et al (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: eastern cooperative oncology group trial E2297. J Clin Oncol 20:3270–3275PubMedCrossRef
5.
Zurück zum Zitat Herrmann R, Bodoky G, Ruhstaller T et al (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss group for clinical cancer research and the Central European cooperative oncology group. J Clin Oncol 25:2212–2217PubMedCrossRef Herrmann R, Bodoky G, Ruhstaller T et al (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss group for clinical cancer research and the Central European cooperative oncology group. J Clin Oncol 25:2212–2217PubMedCrossRef
6.
Zurück zum Zitat Cunningham D, Chau I, Stocken C et al (2009) Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27:5513–5518PubMedCrossRef Cunningham D, Chau I, Stocken C et al (2009) Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27:5513–5518PubMedCrossRef
7.
Zurück zum Zitat Poplin E, Feng Y, Berlin J et al (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30 min infusion) in patients with pancreatic carcinoma E6201: a trial of the eastern cooperative oncology group. J Clin Oncol 27:3778–3785PubMedCrossRef Poplin E, Feng Y, Berlin J et al (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30 min infusion) in patients with pancreatic carcinoma E6201: a trial of the eastern cooperative oncology group. J Clin Oncol 27:3778–3785PubMedCrossRef
8.
Zurück zum Zitat Colucci G, Labianca R, Di Costanzo F et al (2010) Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 28:1645–1651PubMedCrossRef Colucci G, Labianca R, Di Costanzo F et al (2010) Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 28:1645–1651PubMedCrossRef
9.
Zurück zum Zitat Sultana A, Tudur Smith C, Cunningham D et al (2008) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25:2607–2615CrossRef Sultana A, Tudur Smith C, Cunningham D et al (2008) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25:2607–2615CrossRef
10.
Zurück zum Zitat Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 25:1960–1966PubMedCrossRef Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 25:1960–1966PubMedCrossRef
11.
Zurück zum Zitat Sobrero A, Bruzzi P (2009) Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J Clin Oncol 27:5868–5873PubMedCrossRef Sobrero A, Bruzzi P (2009) Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J Clin Oncol 27:5868–5873PubMedCrossRef
12.
Zurück zum Zitat Reni M, Passoni P, Panucci MG et al (2001) Definitive results of phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. J Clin Oncol 19:2679–2686PubMed Reni M, Passoni P, Panucci MG et al (2001) Definitive results of phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. J Clin Oncol 19:2679–2686PubMed
13.
Zurück zum Zitat Reni M, Cordio S, Milandri C et al (2005) Gemcitabine versus cisplatin, epirubicin, 5-fluorouracil, gemcitabine in advanced pancreatic cancer: a phase III trial. Lancet Oncol 6:369–376PubMedCrossRef Reni M, Cordio S, Milandri C et al (2005) Gemcitabine versus cisplatin, epirubicin, 5-fluorouracil, gemcitabine in advanced pancreatic cancer: a phase III trial. Lancet Oncol 6:369–376PubMedCrossRef
14.
Zurück zum Zitat Reni M, Bonetto E, Cordio S et al (2006) Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial. Pancreatology 6:454–463PubMedCrossRef Reni M, Bonetto E, Cordio S et al (2006) Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial. Pancreatology 6:454–463PubMedCrossRef
15.
Zurück zum Zitat Reni M, Cereda S, Bonetto E et al (2007) Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study. Cancer Invest 25:594–598PubMedCrossRef Reni M, Cereda S, Bonetto E et al (2007) Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study. Cancer Invest 25:594–598PubMedCrossRef
16.
Zurück zum Zitat Reni M, Cereda S, Bonetto E et al (2007) Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 59:361–367PubMedCrossRef Reni M, Cereda S, Bonetto E et al (2007) Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 59:361–367PubMedCrossRef
17.
Zurück zum Zitat Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46PubMedCrossRef Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46PubMedCrossRef
18.
Zurück zum Zitat Lenzi R, Yalcin S, Evans DB et al (2002) Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. Cancer Invest 20:464–472PubMedCrossRef Lenzi R, Yalcin S, Evans DB et al (2002) Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. Cancer Invest 20:464–472PubMedCrossRef
19.
Zurück zum Zitat Androulakis N, Kourosis C, Dimopoulos MA et al (1999) Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J Clin Oncol 17:1779–1785PubMed Androulakis N, Kourosis C, Dimopoulos MA et al (1999) Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J Clin Oncol 17:1779–1785PubMed
20.
Zurück zum Zitat Venturini M, Durando A, Garrone O et al (2003) Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. Cancer 97:1174–1180PubMedCrossRef Venturini M, Durando A, Garrone O et al (2003) Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. Cancer 97:1174–1180PubMedCrossRef
21.
Zurück zum Zitat Alexopoulos A, Karamouzis MV, Rigatos G et al (2004) In vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer: general concepts and future perspectives. Semin Oncol 2:25–30CrossRef Alexopoulos A, Karamouzis MV, Rigatos G et al (2004) In vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer: general concepts and future perspectives. Semin Oncol 2:25–30CrossRef
22.
Zurück zum Zitat Rigas JR (2004) Taxane-platinum combinations in advanced non-small cell lung cancer: a review. Oncologist 9:16–23PubMedCrossRef Rigas JR (2004) Taxane-platinum combinations in advanced non-small cell lung cancer: a review. Oncologist 9:16–23PubMedCrossRef
23.
Zurück zum Zitat Sawada N, Ishikawa T, Fukase Y et al (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 4:1013–1019PubMed Sawada N, Ishikawa T, Fukase Y et al (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 4:1013–1019PubMed
24.
Zurück zum Zitat Ricotti L, Tesei A, De Paola F et al (2003) In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines. Clin Cancer Res 9:900–905PubMed Ricotti L, Tesei A, De Paola F et al (2003) In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines. Clin Cancer Res 9:900–905PubMed
25.
Zurück zum Zitat Maeda S, Sugiura T, Saikawa Y et al (2004) Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism. Cancer Sci 95:679–684PubMedCrossRef Maeda S, Sugiura T, Saikawa Y et al (2004) Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism. Cancer Sci 95:679–684PubMedCrossRef
26.
Zurück zum Zitat Greene FL, Page D, Fleming ID et al (eds) (2002) Exocrine pancreas. In: AJCC cancer staging manual, 6th edn. Springer, New York, pp 157–164 Greene FL, Page D, Fleming ID et al (eds) (2002) Exocrine pancreas. In: AJCC cancer staging manual, 6th edn. Springer, New York, pp 157–164
27.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef
28.
Zurück zum Zitat Ajani JA, Welch SR, Raber MN et al (1990) Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8:147–159PubMedCrossRef Ajani JA, Welch SR, Raber MN et al (1990) Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8:147–159PubMedCrossRef
29.
Zurück zum Zitat Reni M, Cereda S, Balzano G et al (2009) Carbohydrate antigen (CA)19–9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 115:2630–2639PubMedCrossRef Reni M, Cereda S, Balzano G et al (2009) Carbohydrate antigen (CA)19–9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 115:2630–2639PubMedCrossRef
30.
Zurück zum Zitat Kulke MH, Tempero MA, Niedzwiecki D et al (2009) Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with Cisplatin, Docetaxel, or Irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol 27:5506–5512PubMedCrossRef Kulke MH, Tempero MA, Niedzwiecki D et al (2009) Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with Cisplatin, Docetaxel, or Irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol 27:5506–5512PubMedCrossRef
31.
Zurück zum Zitat Lutz MP, Van Cutsem E, Wagener T et al (2005) Docetaxel Plus Gemcitabine or Docetaxel Plus Cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European organisation for research and treatment of cancer gastrointestinal group. J Clin Oncol 23:9250–9256PubMedCrossRef Lutz MP, Van Cutsem E, Wagener T et al (2005) Docetaxel Plus Gemcitabine or Docetaxel Plus Cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European organisation for research and treatment of cancer gastrointestinal group. J Clin Oncol 23:9250–9256PubMedCrossRef
32.
Zurück zum Zitat Cascinu S, Gasparini G, Catalano V et al (1999) A phase I–II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian group for the study of digestive tract cancer (GISCAD). Ann Oncol 10:1377–1379PubMedCrossRef Cascinu S, Gasparini G, Catalano V et al (1999) A phase I–II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian group for the study of digestive tract cancer (GISCAD). Ann Oncol 10:1377–1379PubMedCrossRef
33.
Zurück zum Zitat Fine RL, Fogelman DR, Schreibman SM et al (2008) The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 61:167–175PubMedCrossRef Fine RL, Fogelman DR, Schreibman SM et al (2008) The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 61:167–175PubMedCrossRef
34.
Zurück zum Zitat Hess V, Pratsch S, Potthast S et al (2010) Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial. Ann Oncol 21:2390–2395PubMedCrossRef Hess V, Pratsch S, Potthast S et al (2010) Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial. Ann Oncol 21:2390–2395PubMedCrossRef
35.
Zurück zum Zitat Boeck S, Hoehler T, Seipelt G et al (2008) Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann Oncol 19:340–347PubMedCrossRef Boeck S, Hoehler T, Seipelt G et al (2008) Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann Oncol 19:340–347PubMedCrossRef
36.
Zurück zum Zitat Conroy T, Desseigne F, Ychou M et al (2010) Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. Proc Am Soc Clin Oncol 28:abstr 4010 Conroy T, Desseigne F, Ychou M et al (2010) Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. Proc Am Soc Clin Oncol 28:abstr 4010
37.
Zurück zum Zitat Cantore M, Fiorentini G, Luppi G et al (2004) Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective randomized phase III trial of the Italian society for integrated locoregional therapy in oncology. J Chemother 16:34–39 Cantore M, Fiorentini G, Luppi G et al (2004) Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective randomized phase III trial of the Italian society for integrated locoregional therapy in oncology. J Chemother 16:34–39
Metadaten
Titel
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen)
verfasst von
Michele Reni
Stefano Cereda
Alessia Rognone
Carmen Belli
Michele Ghidini
Simonetta Longoni
Clara Fugazza
Sara Rezzonico
Paolo Passoni
Najla Slim
Giampaolo Balzano
Roberto Nicoletti
Stefano Cappio
Claudio Doglioni
Eugenio Villa
Publikationsdatum
01.01.2012
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 1/2012
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-011-1680-2

Weitere Artikel der Ausgabe 1/2012

Cancer Chemotherapy and Pharmacology 1/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.